CSPC Pharmaceutical Group Limited (CHJTF)
OTCMKTS · Delayed Price · Currency is USD
0.9800
0.00 (0.00%)
Oct 22, 2025, 8:00 PM EDT
CSPC Pharmaceutical Group Revenue
CSPC Pharmaceutical Group had revenue of 6.26B CNY in the quarter ending June 30, 2025, a decrease of -14.28%. This brings the company's revenue in the last twelve months to 26.00B, down -17.87% year-over-year. In the year 2024, CSPC Pharmaceutical Group had annual revenue of 29.01B, down -7.76%.
Revenue (ttm)
26.00B CNY
Revenue Growth
-17.87%
P/S Ratio
3.20
Revenue / Employee
1.21M CNY
Employees
21,400
Market Cap
11.61B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.01B | -2.44B | -7.76% |
| Dec 31, 2023 | 31.45B | 513.21M | 1.66% |
| Dec 31, 2022 | 30.94B | 3.07B | 11.02% |
| Dec 31, 2021 | 27.87B | 2.92B | 11.73% |
| Dec 31, 2020 | 24.94B | 2.84B | 12.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
CSPC Pharmaceutical Group News
- 3 months ago - Madrigal in-pact with CSPC Pharma for obesity drug license - Seeking Alpha
- 4 months ago - Medtide Launches Hong Kong IPO to Boost Weight-loss Business - Benzinga
- 4 months ago - AstraZeneca Inks China AI Research Deal For Chronic Diseases - NDTV
- 4 months ago - AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion - Benzinga
- 4 months ago - AstraZeneca signs US$5 billion research deal with China’s CSPC - BNN Bloomberg
- 4 months ago - CSPC Pharma Pursues Licensing Deals After Lackluster Earnings - Benzinga
- 5 months ago - Chinese biotech’s mega drug-licensing deals with multinationals surge - South China Morning Post
- 1 year ago - CSPC Pharmaceutical Group Limited goes ex dividend tomorrow - Seeking Alpha